samplefat-targeting
98%+ · 10mg · Lyophilized
Bulk discount
3+ pcs
€65.55
−5%
5+ pcs
€62.10
−10%
10+ pcs
€58.65
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Adipotide
Prohibitin‑Targeting Peptidomimetic | Experimental Anti‑Obesity
In short
Targeted peptide studied in animal models for selectively inducing apoptosis in the vasculature of white adipose tissue.
Best sellers
Related resources
Ready-to-use starter kit
Adipotide is an experimental chimeric peptide designed to specifically target the blood vessels that supply white adipose tissue. At the molecular level, it binds to specific proteins (prohibitin) on the surface of these vessels and triggers their breakdown, thereby depriving fat cells of nutrients. Scientists study this mechanism in animal models to observe its effects on adipose tissue and metabolism. This product is strictly for laboratory research purposes (research-grade) and is not an approved medication or treatment for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Adipotide (Prohibitin‑TP01) is a chimeric, adipose‑vasculature–targeted peptidomimetic that homes to prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro‑apoptotic D‑(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, but development halted after an early Phase 1 oncology trial; kidney safety signals (reversible proximal tubule changes) remain a key concern.
Selective adipocyte vasculature elimination Prohibitin targeting (MD Anderson) White adipose mass -11% (Barnhart 2011) Tissue-specific apoptosis induction
CKGGRAKDC homes to prohibitin/annexin A2 on white‑fat endothelium; the linked D‑(KLAKLAK)2 disrupts mitochondrial membranes after internalization, triggering localized endothelial apoptosis and adipocyte loss.
Selective WAT vascular targeting produced 7–15% body‑weight loss over 4 weeks in obese macaques.
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Consistent daily timing; monitor hydration
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 5.0
5.0marks
Standard insulin syringe 1 ml (100 marks)
Concentration
5.00mg/ml
Dose volume
0.050ml
U-100 units
5.0units
Doses per vial
40doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (10 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Consistent daily timing; monitor hydration
Sanitize hands and workspace; swab vial septum.
Inject BAC water slowly down the vial wall; do not jet onto powder.
Gently swirl until fully dissolved (do not shake).
Label with concentration/date; store at 2–8°C; discard per lab SOP.
Not ‑approved; investigational/educational only.
Monitor serum creatinine, BUN, urinalysis, electrolytes weekly in animal studies.
Kidney: dose‑dependent, largely reversible proximal tubule changes observed in primates.
Avoid dehydration; consider temporarily pausing if creatinine rises persistently.
Pregnancy/lactation: not studied; avoid.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Human adipose targeting – imaging validation (2018)
Human adipose tissue (ex vivo) & mouse in vivo | CKGGRAKDC MRI probe | Single/short courses | Specific WAT targeting demonstrated
Molecular MRI using CKGGRAKDC confirmed prohibitin‑based adipose targeting, supporting the translational targeting concept.
View the studyObese rhesus macaques – fixed‑dose efficacy & safety (2011)
Rhesus macaques | 0.43 mg/kg SC daily | 28 days + 28‑day recovery | 7.4–14.7% weight loss; insulin resistance improved; mild, dose‑dependent, reversible proximal tubule changes
White‑adipose vasculature targeting led to rapid fat mass reduction and improved insulin dynamics. Kidney signals (creatinine rise, tubular changes) were dose‑related and largely reversible after discontinuation.
View the studyRhesus macaques – dose‑finding (2011)
Rhesus macaques | 0.10 → 0.25 → 0.43 → 0.75 mg/kg SC (escalated) | 63 days total | Dose‑dependent efficacy; renal safety signal >0.25 mg/kg
Identified 0.43 mg/kg SC daily as the optimal primate dose balancing efficacy and renal safety for subsequent fixed‑dose testing.
View the studyFirst‑in‑human Phase 1 (oncology/weight) – terminated (2010–2013)
Adults with metastatic prostate cancer & obesity | Subcutaneous, dose‑escalation | Early termination; limited enrollment
Single‑center Phase 1 (MD Anderson) of Prohibitin‑TP01 in advanced prostate cancer patients with obesity; development discontinued before efficacy read‑out.
View the studyRodent proof‑of‑concept – targeted adipose vascular ablation (2004)
Mice (diet‑induced obesity) | CKGGRAKDC‑GG‑D(KLAKLAK)2 | Daily x 4 weeks | ~30% weight reduction; adipose vascular apoptosis; metabolic normalization
In vivo phage display identified CKGGRAKDC as a white‑fat vasculature 'ZIP code' (prohibitin receptor). Fusing this ligand to D‑(KLAKLAK)2 induced targeted apoptosis and robust fat loss.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
